| |
|
|
Session 71
Poster Presentations Resistance to HIV-1 Protease Inhibitors Tuesday 1:30 - 3:30 pm Hall A |
| 593 | SIV Protease Sequences in a RT/SHIV Background are Sensitive to HIV-1 Protease Inhibitors E. Paintsil*, L.Alexander Yale Univ, New Haven, CT |
| 594 | Genotypic Basis of Variation in Protease Susceptibility in Primary HIV Infection Analyzed with Machine Learning AJ Leigh Brown*1,2, SDW Frost2, B Good2, ES Daar3, V Simon4, M Markowitz4, AC Collier5, E Connick6, B Conway7, JB Margolick8, JP Routy9, J Corbeil2, N Hellmann10, DD Richman2, SJ Little2 1Univ of Edinburgh, Scotland; 2Univ of California at San Diego; 3Harbor-UCLA, Los Angeles, CA; 4Aaron Diamond AIDS Res Ctr, New York, NY; 5Univ of Washington, Seattle; 6Univ of Colorado, Denver; 7Univ of British Columbia, Vancouver, Canada; 8Johns Hopkins Univ, Baltimore, MD; 9McGill Univ Hlth Ctr, Montreal, Canada; and 10ViroLogic, San Francisco, CA |
| 595 | Identification of the Minimal Conserved Structure of the HIV-protease under the Presence and Absence of Drug Pressure F Ceccherini-Silberstein*1, A Bertoli2, F Forbici2, F Erba1, L Marcon3, S Aquaro1, C Balotta4, S Giannella2, R D'Arrigo2, MC Bellocchi2, C Gori2, MP Trotta2, A d'Arminio Monforte4, A Antinori2, CF Perno1,2 1Univ of Rome Tor Vergata, Italy; 2Inst Natl per le Malattie Infettive L Spallanzani, Rome, Italy; 3Univ of Padua, Italy; and 4Univ of Milan, Italy |
| 596 | Baseline Phenotypic Suceptibility to Tipranavir/Ritonavir is Retained in Isolates from Patients with Multiple Protease Inhibitor Experience (BI 1182.52) D Cooper*1, D Hall2, D Jayaweera3, S Moreno4, C Katlama5, S Schneider 6, L Minoli7, P Yeni8, R Steigbigel9, S McCallister2, V Kohlbrenner2, E Cuaresma2, J. Sabo2, D Mayers2 1St Vincent Hosp, Darlinghurst, Australia; 2Boehringer Ingelheim, Ridgefield, CT; 3Jackson Med Ctr, Miami FL; 4Hosp Ramón y Cajal, Madrid, Spain; 5Hosp de la Pitie Salpetriere, Paris, France; 6Living Hope Clin Trials, Long Beach, CA; 7Inst di Ricovero e Cura a Carattere Sci (IRCCS) Policlinico San Matteo, Pavia, Italy; 8Groupe Hosp Bichat-Claude Bernard, Paris, France; and 9Univ of New York at Stony Brook |
| 597 | Emergence of Atazanavir Resistance and Maintenance of Susceptibility to Other PIs is Associated with an I50L Substitution in HIV Protease R. Colonno*1, R. Rose1, C. Cianci1, G. Aldrovandi2, N. Parkin3, J. Friborg1 1Bristol-Myers Squibb, Wallingford, CT; 2Univ of Alabama at Birmingham; and 3ViroLogic, San Francisco, CA |
| 598 | GW433908 in ART-naive Subjects: Absence of Resistance at 48 Weeks with Boosted Regimen and APV-like Resistance Profile with Unboosted Regimen S. Macmanus1, P.Yates1, S. White2, N. Richards2, W. Snowden*1 1GlaxoSmithKline, Stevenage, UK and 2GlaxoSmithKline, Greenford, UK |
| 599 | Impact of Amino-acid Insertions in HIV-1 p6 PTAP Region on the Virological Response to Amprenavir in the NARVAL Trial S. Lastere*1, C. Dalban2, G. Collin1, D. Descamps1, P.M. Girard3, F. Clavel4, D. Costagliola2, F. Brun-Vezinet1 1Bichat-Claude Bernard Hosp, Paris, France; 2INSERM EMI0214, Paris, France; 3St Antoine Hosp, Paris, France; and 4INSERM U552, Paris, France |
| 600 | Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-infected Subjects Receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy D. Kempf*, M. King, E. Bauer, J. Moseley, B. Bernstein, S. Brun, E. Sun Abbott Labs, Abbott Park, IL |
| 601 | Role of Resistance and Fitness in Driving the Evolution of the Protease in Patients Failing Treatment with Protease Inhibitors C. Charpentier, D. Lecossier, F. Clavel, A. J. Hance* INSERM U552, Hosp Bichat-Claude Bernard, Paris, France |
| 602 | Mutation 36I of the Protease Region Before Starting Therapy Facilitates the Appearance of L90M in Patients Failing their First PI-HAART Regimen CF Perno*1, A Cozzi-Lepri2, C Balotta3, F Forbici1, M Violin3, A De Luca4, S Rusconi3, G Ballardini5, E Petrelli6, E Tufo7, AN Phillips2, A d'Arminio-Monforte3 1Inst Natl per le Malattie Infettive L Spallanzani, Rome, Italy; 2Royal Free Univ Coll Med Sch, London, UK; 3Univ of Milan, Italy; 4Catholic Univ, Rome, Italy; 5St Maria delle Croci Hosp, Ravenna, Utaly; 6San Salvatore Hosp, Pesaro, Italy; and 7Hosp of Latina, Italy |
| 603 | Determination of an Indinavir Susceptibility Cutoff for Indinavir-ritonavir Containing Regimens J Szumiloski*1, H. Wilson1, R. Campo2, N. Miller2, H. Rice3, A. Zolopa3, D. Klein4, M. Horburg5, N. Hellmann6, M. Bates6, J. Condra1 1Merck Res Labs, West Point, PA; 2Univ of Miami, FL; 3Stanford Univ, Palo Alto, CA; 4Kaiser Permanente Med Ctr, Hayward, CA; 5Kaiser Permanente Med Ctr, Santa Clara, CA; and 6ViroLogic, San Francisco, CA |
| 604 | Resistant-Repellant HIV-1 Protease Inhibitors: How They Work J. Erickson*, S. Gulnik, A. Silva, M. Eissenstat Sequoia Pharm, Inc, Gaithersburg, MD |